CVR: 34459975
Previous names: SYNACTION PHARMA ApS
SYNACT PHARMA ApS is a Danish company of the type Anpartsselskab based in Holte, founded in 2012. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named SYNACTION PHARMA ApS. The management consists of Jeppe Øvli Øvlesen, Thomas Boesen and Ann Kristin Brøgger Led. The company is owned by SynAct Pharma AB. In 2025, the company reported a gross profit of DKK -53,194,923 and a net result of DKK -59,812,937 compared with DKK -30,477,376 the year before. Equity amounted to DKK 20,295,649.
Your company? Claim the profile and show your logo, website and social channels — for free.
Claim this profileSelskabets formål er at udvikle lægemidler og dermed relateret virksomhed samt enhver aktivitet, der efter direktionens skøn står i forbindelse hermed.
| Year | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2025 | -53.2 mio. | -59.8 mio. | 32 mio. | 20.3 mio. | 0 | |
| 2024 | -26.3 mio. | -30.5 mio. | 37.8 mio. | 25.1 mio. | 4 | |
| 2023 | -63.4 mio. | -65.4 mio. | 26.8 mio. | 15.6 mio. | 3 | |
| 2022 | -47 mio. | -49.8 mio. | 37.9 mio. | 34 mio. | 3 | |
| 2021 | -43.4 mio. | -41.2 mio. | 13.5 mio. | 6.6 mio. | 2 | |
| 2020 | -16.7 mio. | -14 mio. | 12.7 mio. | 11.4 mio. | - | |
| 2019 | -11.5 mio. | -9.8 mio. | 6.1 mio. | -21.8 mio. | - | |
| 2018 | -16.8 mio. | -13.6 mio. | 7.4 mio. | -12 mio. | - | |
| 2017 | -10 mio. | -8.3 mio. | 10.1 mio. | 1.6 mio. | - | |
| 2016 | -9.9 mio. | -8.9 mio. | 21.3 mio. | 9.9 mio. | - | |
| 2015 | -309 t. | -783 t. | 306 t. | -3.9 mio. | - | |
| 2014 | -343 t. | -768 t. | 568 t. | -3.1 mio. | - | |
| 2013 | -953 t. | -1.1 mio. | - | -2.3 mio. | - |
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationCompared to 129 companies in Fremstilling af farmaceutiske præparater
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
SYNACT PHARMA ApS has published its annual report for 2025. Gross profit came to DKK -53,194,923, and the net result was DKK -59,812,937.
Contact info changed: new phone: 28447567, new email: [email protected] (March 11, 2026).
Contact info changed: new phone: 28447567, new email: [email protected] (March 10, 2026).
As of March 10, 2026, Ann Kristin Brøgger Led is registered as director of SYNACT PHARMA ApS.
As of March 10, 2026, Björn Uno Bernhard Westberg has stepped down as director of SYNACT PHARMA ApS.
SYNACT PHARMA ApS has published its annual report for 2024. Gross profit came to DKK -26,274,866, and the net result was DKK -30,477,376.
SYNACT PHARMA ApS has published its annual report for 2023. Gross profit came to DKK -63,448,353, and the net result was DKK -65,408,926.
As of March 20, 2024, Jeppe Øvli Øvlesen is registered as adm. dir. of SYNACT PHARMA ApS.
As of March 20, 2024, Torbjørn Bjerke has stepped down as adm. dir. of SYNACT PHARMA ApS.
As of June 15, 2023, Björn Uno Bernhard Westberg is registered as director of SYNACT PHARMA ApS.
As of June 15, 2023, Patrik Renblad has stepped down as director of SYNACT PHARMA ApS.
SYNACT PHARMA ApS has published its annual report for 2022. Gross profit came to DKK -46,951,479, and the net result was DKK -49,780,297.
As of May 25, 2023, Torbjørn Bjerke is registered as adm. dir. of SYNACT PHARMA ApS.
As of May 25, 2023, Thomas Boesen is registered as director of SYNACT PHARMA ApS.
As of May 25, 2023, Jeppe Øvli Øvlesen has stepped down as adm. dir. of SYNACT PHARMA ApS.
As of August 15, 2022, KPMG P/S has been appointed auditor of SYNACT PHARMA ApS.
As of August 15, 2022, Forvis Mazars Statsautoriseret Revisionspartnerselskab has stepped down as auditor of SYNACT PHARMA ApS.
SYNACT PHARMA ApS has published its annual report for 2021. Gross profit came to DKK -43,429,977, and the net result was DKK -41,156,629.
As of January 18, 2022, Patrik Renblad is registered as director of SYNACT PHARMA ApS.
As of January 18, 2022, Henrik Stage has stepped down as director of SYNACT PHARMA ApS.
SYNACT PHARMA ApS has published its annual report for 2020. Gross profit came to DKK -16,676,255, and the net result was DKK -14,002,315.
SYNACT PHARMA ApS has published its annual report for 2019. Gross profit came to DKK -11,468,376, and the net result was DKK -9,826,308.
SYNACT PHARMA ApS has published its annual report for 2018. Gross profit came to DKK -16,809,905, and the net result was DKK -13,647,343.
SYNACT PHARMA ApS has published its annual report for 2017. Gross profit came to DKK -9,991,876, and the net result was DKK -8,278,722.
SYNACT PHARMA ApS has published its annual report for 2016. Gross profit came to DKK -9,884,650, and the net result was DKK -8,884,785.
As of April 12, 2016, is registered as an owner of SYNACT PHARMA ApS with an ownership share of 100%.
SYNACT PHARMA ApS has published its annual report for 2015. Gross profit came to DKK -309,046, and the net result was DKK -782,555.
As of March 17, 2016, Forvis Mazars Statsautoriseret Revisionspartnerselskab has been appointed auditor of SYNACT PHARMA ApS.
As of March 17, 2016, DANSK REVISION MARIAGERFJORD, STATSAUTORISERET REVISIONSPARTNERSELSKAB has stepped down as auditor of SYNACT PHARMA ApS.
As of March 10, 2016, Otto Bjerg Hausgaard has left the board of directors of SYNACT PHARMA ApS.
As of March 10, 2016, Sigbjørn Georg Nielsen Kjærgård has left the board of directors of SYNACT PHARMA ApS.
As of March 10, 2016, Thomas Engelbrecht Nordkild Jonassen has left the board of directors of SYNACT PHARMA ApS.
As of March 10, 2016, Henrik Stage is registered as director of SYNACT PHARMA ApS.
As of August 17, 2015, Thomas Engelbrecht Nordkild Jonassen has joined the board of directors of SYNACT PHARMA ApS.
As of August 17, 2015, Jeppe Øvli Øvlesen is registered as adm. dir. of SYNACT PHARMA ApS.
As of August 17, 2015, Sigbjørn Georg Nielsen Kjærgård has stepped down as adm. dir. of SYNACT PHARMA ApS.
SYNACT PHARMA ApS has published its annual report for 2014. Gross profit came to DKK -343,449, and the net result was DKK -768,256.
As of February 16, 2015, Otto Bjerg Hausgaard has joined the board of directors of SYNACT PHARMA ApS.
As of February 16, 2015, Uli Alf Hacksell has left the board of directors of SYNACT PHARMA ApS.
As of February 9, 2015, Jørn Frederik Falch has left the board of directors of SYNACT PHARMA ApS.
SYNACT PHARMA ApS has published its annual report for 2013. Gross profit came to DKK -952,851, and the net result was DKK -1,061,402.
As of December 16, 2013, Jørn Frederik Falch has joined the board of directors of SYNACT PHARMA ApS.
As of December 16, 2013, Uli Alf Hacksell has joined the board of directors of SYNACT PHARMA ApS.
SYNACT PHARMA ApS has published its interim report for the period March 14, 2012 – December 31, 2012.
As of August 14, 2012, Sigbjørn Georg Nielsen Kjærgård has joined the board of directors of SYNACT PHARMA ApS.
As of June 28, 2012, DANSK REVISION MARIAGERFJORD, STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of SYNACT PHARMA ApS.
As of June 28, 2012, Bruno Sten Rosenkrans Jensen has stepped down as auditor of SYNACT PHARMA ApS.
On May 1, 2012, the company changed its name from SYNACTION PHARMA ApS to SYNACT PHARMA ApS.
As of March 14, 2012, Bruno Sten Rosenkrans Jensen has been appointed auditor of SYNACT PHARMA ApS.
As of March 14, 2012, Sigbjørn Georg Nielsen Kjærgård is registered as adm. dir. of SYNACT PHARMA ApS.
SYNACT PHARMA ApS was founded on March 14, 2012.
Companies in the same industry and area
CVR 35419543
CVR 40259724
CVR 38034871
CVR 37016845
CVR 16279099
companydata.dk